drugset / Trial / NCT03431948
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .
Timeline
- Start
- 2018-03-15
- Primary completion
- 2020-02-29
- Completion
- 2022-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabiralizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 8 mg | Intravenous |